SYNAPSE assumes a critical role within the CLAIMS project consortium by overseeing communication, dissemination, and exploitation activities, while also supporting the Project Coordinator on the day-to-day management activities. With a strong dedication to fostering effective communication and enabling seamless coordination among team members, SYNAPSE brings a wealth of experience in managing cross-project collaborations and coordinating diverse working groups. Leveraging our deep knowledge in these areas, our work will be focused to contribute significantly to the successful implementation of the project.
Multiple Sclerosis is a devastating autoimmune disorder of the central nervous system, affecting an estimated 700,000 patients in the EU and over 2.8 million patients globally. To date, there is no cure for MS. Multiple disease-modifying treatments are on the market that focus on the prevention of the acute inflammatory relapses of the disease. While such relapses are known to result in cumulative disease worsening if left untreated, recent evidence suggests that progression independent of relapse activity may instead be the most important driver of long-term cumulative disability worsening.
“In light of the serious burden Multiple Sclerosis imposes on people having to live with this condition any attempt to improve prediction of disease course on an individual level is a huge leap for patients. CLAIMS will make a relevant contribution to advancing the personalized provision of care to patients with MS.“ - Prof. Dr. Paul, ECRC, coordinator of CLAIMS
The CLAIMS project aims to address the urgent need for a more data-driven and personalized clinical decision-support tool for these patients, one that addresses the new insights in disease worsening due to both relapses and disease progression independent of relapses, and as such supports optimal treatment decisions and improved long-term patient outcomes. As such, our mission is to develop, validate, and seek regulatory approval for a companion diagnostic platform that provides a holistic view of each patient.
“The challenge in MS care is to provide individual patients with the right drug at the right time in order to preserve long-term neurological function. There is a great promise in implementing digital solutions to further improve MS care. With the CLAIMS project, we aim to use recent advances in deep learning-based AI for novel biomarker assessments and decision models to generate an improved understanding of disability worsening in MS, and to translate this to tools that support optimal treatment decisions in daily clinical routine.” - Annemie Ribbens, project lead for CLAIMS at Icometrix
Fifteen partners from nine different countries are involved with this prestigious project, bringing together a range of multidisciplinary expertise from clinical, scientific, and technical fields:
Source: Press Release
The CLAIMS (Clinical impact through AI-assisted MS care) project will run over the next 4 years to realize a companion diagnostic platform supporting the assessment and specification of disease worsening in Multiple Sclerosis (MS), and making data-driven precision medicine a reality for patients with MS (pwMS).